KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer.

Ian H Kunkler, Nicola S Russell, Niall Anderson, Richard Sainsbury, J Michael Dixon, David Cameron, Juliette Loncaster, Matthew Hatton, Helen Westenberg, Jackie Clarke, Heather McCarty, Rhun Evans, Konstantinos Geropantas, Virginia Wolstenholme, Abdulla Alhasso, Pamela Woodings, Lisa Barraclough, Neil Bayman, Richard Welch, Fidelis Muturi, Tracy McEleney, Jacqueline Burns, Kathleen Riddle, Eve Macdonald, Joanna Dunlop, Nicole Sergenson, Geertjan van Tienhoven, Karen J Taylor, John M S Bartlett, Tammy Piper, Galina Velikova, Edwin Aird, Boon Chua, Coen Hurkmans, Karen Venables, Linda J Williams, Jeremy S Thomas, Andrew M Hanby, Marjory Maclennan, Susan Cleator, Eldo T Verghese, Yexiong Li, Shulian Wang, Peter Canney, SUPREMO Trial Investigators, Sunil

N Engl J Med 393(18) 1771-1783

PMID41191939
PMCIDPMC7618363
DOI10.1056/NEJMoa2412225
发表日期2025-11-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: The role of postmastectomy chest-wall irradiation in patients with breast cancer classified as pN1 (with involvement of one to three axillary nodes) or pN0 (pathologically node negative) with additional risk factors is uncertain. METHODS: In this international, phase 3, randomized trial, we evaluated the omission of chest-wall irradiation in women with "intermediate-risk" breast cancer - defined as cancer that was stage pT1N1, pT2N1, or pT3N0 or stage pT2N0 with a histologic grade of 3, lymphovascular invasion, or both (tumor size: T1, ≤2 cm; T2, >2 cm to 5 cm; or T3, >5 cm) - that was treated with mastectomy, an axillary procedure, and systemic therapy. Patients were assigned to undergo chest-wall irradiation (40 to 50 Gy; the irradiation group) or not to undergo chest-wall irradiation (the no-irradiation group). The primary end point was overall survival, with 10 years of follow-up. Chest-wall recurrence, regional recurrence, disease-free survival, distant metastasis-free survival, causes of death, and radiation-related adverse events were also assessed. RESULTS: The intention-to-treat population included 808 patients in the irradiation group and 799 in the no-irradiation group. The median follow up was 9.6 years. Overall survival was 81.4% with chest-wall irradiation and 81.9% with no chest-wall irradiation according to 10-year Kaplan-Meier estimates (hazard ratio for death, 1.04; 95% confidence interval [CI], 0.82 to 1.30; P = 0.80). A total of 29 patients had a chest-wall recurrence - 9 (1.1%) in the irradiation group and 20 (2.5%) in the no-irradiation group (between-group difference, <2 percentage points; hazard ratio, 0.45; 95% CI, 0.20 to 0.99). Disease-free survival was 76.2% in the irradiation group and 75.5% in the no-irradiation group (hazard ratio for recurrence or death, 0.97; 95% CI, 0.79 to 1.18), and distant metastasis-free survival was 78.2% and 79.2%, respectively (hazard ratio for distant metastasis or death, 1.06; 95% CI, 0.86 to 1.31). CONCLUSIONS: In this trial, chest-wall irradiation did not result in higher overall survival than no chest-wall irradiation among patients with intermediate-risk, early breast cancer treated with mastectomy and contemporary adjuvant systemic therapy. (Funded by the Medical Research Council and others; SUPREMO ISRCTN Clinical Study Registry number, 61145589.).

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2. Kaplan-Meier plot for unadjusted overall survival in ITT population. Note that for clarity, the horizontal scale has been truncated at 10 years (excluding a small proportion of follow-up extending beyond this time period).

Figure_2

overall survival

Figure 2 · Panel Figure_2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Figure_2 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Figure 3

Figure 3. Kaplan-Meier plots for unadjusted secondary endpoints in ITT population. Note that for clarity, the horizontal scale excludes follow-up longer than 10 years. A: Chest wall recurrence-free survival. B: Locoregional recurrence-free survival. C: Distant metastasis-free survival. D: Disease-free survival.

A

Chest wall recurrence-free survival

Figure 3 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. CONSORT Diagram
非 KM Figure
Figure 4Figure 4. Forest plot for subgroup analyses of primary endpoint of overall survival in ITT population. Subgroups considered are age groups, nodal status and molecular subtype. For comparison, the HR for randomised treatment (stratified only by center) is provided at the bottom of the plot.
非 KM Figure